Microbot Medical Secures Early Adoption for LIBERTY System in Key Clinical Trial Sites

Event summary

  • Microbot Medical's LIBERTY Endovascular Robotic System has been adopted by multiple accounts across key territories, including two ACCESS-PVI pivotal clinical trial sites.
  • The company will attend the Annual Global Embolization Symposium & Technologies (GEST) Conference in New York City from May 14-17, 2026.
  • Alon Tamir has been appointed as Vice President of Sales, EMEA, to lead commercialization across key international markets.
  • The company expects to benefit from updated medical guidelines aimed at reducing radiation exposure and improving ergonomic challenges in interventional care.

The big picture

Microbot Medical's early adoption of the LIBERTY System in key clinical trial sites underscores the growing commercial interest in robotic endovascular solutions. The company's participation in the GEST conference and the appointment of a new sales leader for the EMEA region signal a strategic push to expand its footprint beyond the U.S. This aligns with broader industry trends towards reducing radiation exposure and improving ergonomic challenges in interventional care, positioning Microbot Medical to capitalize on evolving medical guidelines and technological advancements.

What we're watching

Adoption Momentum
Whether the early adoption by clinical trial sites will translate into sustained commercial success and broader market acceptance.
Conference Impact
The pace at which participation in the GEST conference will drive further peer-to-peer communications and physician interest in the LIBERTY system.
International Expansion
How the appointment of Alon Tamir as Vice President of Sales, EMEA, will affect the company's ability to establish a global commercial infrastructure.